Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib

被引：40
作者：
Schmid, Hansjoerg [1 ]
Jaeger, Bernadette A. S. [2 ]
Lohse, Judith [2 ]
Suttorp, Meinolf [2 ]
机构：
[1] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-3000 Hannover, Germany
[2] Univ Hosp Carl Gustav Carus, Div Pediat Hematol & Oncol, Dresden, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; BONE; MESYLATE; CHILDREN; THERAPY; PHASE; CML;
D O I：
10.3324/haematol.2009.008359
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1177 / 1179
页数：3
相关论文
共 13 条
[1]  
[Anonymous], 1997, Sozialpadiatrie, V19, P20
[2]   Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].
Berman, E ;
Nicolaides, M ;
Maki, RG ;
Fleisher, M ;
Chanel, S ;
Scheu, K ;
Wilson, BA ;
Heller, G ;
Sauter, NP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013
[3]   Long-term imatinib therapy promotes bone formation in CML patients [J].
Fitter, Stephen ;
Dewar, Andrea L. ;
Kostakis, Panagiota ;
To, L. Bik ;
Hughes, Timothy P. ;
Roberts, Marion M. ;
Lynch, Kevin ;
Vernon-Roberts, Barrie ;
Zannettino, Andrew C. W. .
BLOOD, 2008, 111 (05) :2538-2547
[4]   URINARY PYRIDINOLINE AND DEOXYPYRIDINOLINE IN HEALTHY-CHILDREN AND IN CHILDREN WITH GROWTH-HORMONE DEFICIENCY [J].
FUJIMOTO, S ;
KUBO, T ;
TANAKA, H ;
MIURA, M ;
SEINO, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (06) :1922-1928
[5]   Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia [J].
Jonsson, Sofia ;
Olsson, Bob ;
Ohlsson, Claes ;
Lorentzon, Mattias ;
Mellstrom, Dan ;
Wadenvik, Hans .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (07) :1101-1103
[6]   Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty [J].
Mariani, Stefania ;
Giona, Fiorina ;
Basciani, Sabrina ;
Brama, Marina ;
Gnessi, Lucia .
LANCET, 2008, 372 (9633) :111-112
[7]   Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation [J].
Millot, F ;
Guilhot, J ;
Nelken, B ;
Leblanc, T ;
De Bont, ES ;
Békassy, AN ;
Gadner, H ;
Sufliarska, S ;
Stary, J ;
Gschaidmeier, H ;
Guilhot, F ;
Suttorp, M .
LEUKEMIA, 2006, 20 (02) :187-192
[8]   Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms [J].
O'Sullivan, Susannah ;
Naot, Dorit ;
Callon, Karen ;
Porteous, Fran ;
Horne, Anne ;
Wattie, Diana ;
Watson, Maureen ;
Cornish, Jill ;
Browett, Peter ;
Grey, Andrew .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (11) :1679-1689
[9]   Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response [J].
Osorio, S. ;
Noblejas, A. Garcia ;
Duran, A. ;
Steegmann, J. L. .
AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) :394-395
[10]   Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT [J].
Suttorp, M. .
BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 2) :S40-S46
12